Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

Among agents in the clinic, AB928 is the only antagonist of A2bR, found on both myeloid cells and cancer cells.